Supporting Patients’ Emotional Barriers to Weight Loss

December 18, 2024

In this PharmaPhorum byline, Pleio’s Chief Experience Officer Abby Reynolds explores how pharmaceutical companies can better support patients using GLP-1s by addressing the emotional barriers to weight loss. From stigma and social isolation to misinformation and adherence challenges, Reynolds makes the case for human-first, personalized patient support programs that foster connection, resilience, and real-world success with GLP-1 therapy.